[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Radiopharmaceuticals (Nuclear Medicine) Market, 2012 to 2023

January 2018 | 206 pages | ID: RE3F90C6B6CEN
Precision Business Insights (PBI)

US$ 4,400.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Radiopharmaceuticals (Nuclear Medicine) Market: By Product Type (Diagnostic Radiopharmaceuticals (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals) and Therapeutic Radiopharmaceuticals (Beta Emitters, Alpha emitters, Brachytherapy, and Others)), By Application (Oncology, Neurological disorders, Cardiovascular diseases, Thyroid, and Others), By Route of Administration (Oral, Inhalation, and Parenteral) By End User (Hospitals, Clinics, Diagnostic Centers, and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Global Radiopharmaceuticals (Nuclear Medicine) Market Outline:

Global radiopharmaceuticals (nuclear medicine) market report gives a comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application area, route of administration, end user, and geographic regions. This report studies Global radiopharmaceuticals (nuclear medicine) market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed radiopharmaceuticals market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the Global radiopharmaceuticals (nuclear medicine) market report include suppliers, manufacturers, marketers, policymakers, and healthcare service providers engaged in manufacturing, supply and prescribing of radiopharmaceuticals.

Radiopharmaceuticals (Nuclear Medicine) Market:

Global radiopharmaceuticals (nuclear medicine) market estimated to be valued US$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. The market for radiopharmaceuticals projected to reach US$ 8,564 Mn by 2023 owing to increasing adoption of radiotherapeutic and diagnostic procedures across the globe.

Growing prevalence of cancer and cardiovascular diseases expected to drive adoption of radiopharmaceuticals across the globe

The global radiopharmaceuticals (nuclear medicine) market is growing at a significant CAGR due to rising in the prevalence of various types of cancers and cardiovascular diseases. The growing prevalence of various cancers resulted in an increased adoption of radiopharmaceuticals in diagnosis and treatment of several cancers in developed economies. For instance, according to globocan cancer statistics, There were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 million people living with cancer (within 5 years of diagnosis) in 2012 worldwide. Moreover, advances in technology such as introduction of PET radiotracers and targeted radioimmunotherapies expected to drive the overall market revenue growth over the forecast period

Emergence of radiopharmaceuticals (nuclear medicine) as safer alternative to the conventional diagnosis

The development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as an effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.

North America accounts for larger revenue share in global radiopharmaceuticals (nuclear medicine) market

North America market holds the higher revenue share in global radiopharmaceuticals (nuclear medicine) market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia Pacific radiopharmaceuticals (nuclear medicine) market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region

Competition Assessment

Key players profiled in the global radiopharmaceuticals (nuclear medicine) market include:

Advanced Accelerator Applications S.A. (France)
Bayer AG (Germany)
Bracco Imaging S.p.A (Italy)
Cardinal Health, Inc. (U.S.)
Eli Lilly and Co. (U.S.)
GE Healthcare (U.S.)
IBA Molecular Imaging (Belgium)
Jubilant Life Sciences Ltd (India)
Lantheus Medical Imaging, Inc. (U.S.)
Mallinckrodt plc (Ireland)
Navidea Biopharmaceutical (U.S.)
Nordion, Inc. (Canada)
Siemens Healthineers (Germany)

Players in the radiopharmaceuticals (nuclear medicine) market are focusing on expanding product portfolio, acquisitions to garner larger market revenue share in global radiopharmaceuticals (nuclear medicine) market

1. EXECUTIVE SUMMARY

2. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET INTRODUCTION

2.1. Global Radiopharmaceuticals (Nuclear Medicine) Market – Taxonomy
2.2. Global Radiopharmaceuticals (Nuclear Medicine) Market –Definitions
  2.2.1. Product Type
  2.2.2. Application
  2.2.3. Route of Administration
  2.2.4. End-User

3. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Factors Impact Analysis
3.6. Global Radiopharmaceuticals (Nuclear Medicine) Market – Regulations
  3.6.1. U.S.
  3.6.2. Europe

4. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET, BY PRODUCT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Diagnostic Radiopharmaceuticals
  5.1.1. SPECT Radiopharmaceuticals
    5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.1.1.3. Market Opportunity Analysis
  5.1.2. PET Radiopharmaceuticals
    5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.1.2.3. Market Opportunity Analysis
5.2. Therapeutic Radiopharmaceuticals
  5.2.1. Beta Emitters
    5.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.2.1.3. Market Opportunity Analysis
  5.2.2. Alpha emitters
    5.2.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.2.2.3. Market Opportunity Analysis
  5.2.3. Brachytherapy
    5.2.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.2.3.3. Market Opportunity Analysis
  5.2.4. Others
    5.2.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
    5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
    5.2.4.3. Market Opportunity Analysis

6. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Oncology
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Neurological disorders
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Cardiovascular diseases
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Thyroid
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis
6.5. Others
  6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.5.3. Market Opportunity Analysis

7. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Oral
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Inhalation
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Parenteral
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY END-USER, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Hospitals
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Clinics
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Diagnostic Centers
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Research Institutes
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis

9. GLOBAL RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America
  9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.1.3. Market Opportunity Analysis
9.2. Europe
  9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
  9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.3.3. Market Opportunity Analysis
9.4. Latin America
  9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
  9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  9.5.3. Market Opportunity Analysis
9.6. Global Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Region, 2017 – 2023

10. NORTH AMERICA RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Diagnostic Radiopharmaceuticals
    10.1.1.1. SPECT Radiopharmaceuticals
    10.1.1.2. PET Radiopharmaceuticals
  10.1.2. Therapeutic Radiopharmaceuticals
    10.1.2.1. Beta Emitters
    10.1.2.2. Alpha emitters
    10.1.2.3. Brachytherapy
    10.1.2.4. Others
10.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.2.1. Oncology
  10.2.2. Neurological disorders
  10.2.3. Cardiovascular diseases
  10.2.4. Thyroid
  10.2.5. Others
10.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.3.1. Oral
  10.3.2. Inhalation
  10.3.3. Parenteral
10.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Hospitals
  10.4.2. Clinics
  10.4.3. Diagnostic Centers
  10.4.4. Research Institutes
10.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  10.5.1. U.S.
  10.5.2. Canada
10.6. North America Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Country, 2017 – 2023
10.7. North America Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends

11. EUROPE RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Diagnostic Radiopharmaceuticals
    11.1.1.1. SPECT Radiopharmaceuticals
    11.1.1.2. PET Radiopharmaceuticals
  11.1.2. Therapeutic Radiopharmaceuticals
    11.1.2.1. Beta Emitters
    11.1.2.2. Alpha emitters
    11.1.2.3. Brachytherapy
    11.1.2.4. Others
11.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.2.1. Oncology
  11.2.2. Neurological disorders
  11.2.3. Cardiovascular diseases
  11.2.4. Thyroid
  11.2.5. Others
11.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.3.1. Oral
  11.3.2. Inhalation
  11.3.3. Parenteral
11.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.4.1. Hospitals
  11.4.2. Clinics
  11.4.3. Diagnostic Centers
  11.4.4. Research Institutes
11.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  11.5.1. Germany
  11.5.2. UK
  11.5.3. France
  11.5.4. Spain
  11.5.5. Italy
  11.5.6. Russia
  11.5.7. Poland
  11.5.8. Rest of Europe
11.6. Europe Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User,and Country, 2017 – 2023
11.7. Europe Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends

12. ASIA-PACIFIC RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Diagnostic Radiopharmaceuticals
    12.1.1.1. SPECT Radiopharmaceuticals
    12.1.1.2. PET Radiopharmaceuticals
  12.1.2. Therapeutic Radiopharmaceuticals
    12.1.2.1. Beta Emitters
    12.1.2.2. Alpha emitters
    12.1.2.3. Brachytherapy
    12.1.2.4. Others
12.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.2.1. Oncology
  12.2.2. Neurological disorders
  12.2.3. Cardiovascular diseases
  12.2.4. Thyroid
  12.2.5. Others
12.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.3.1. Oral
  12.3.2. Inhalation
  12.3.3. Parenteral
12.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Hospitals
  12.4.2. Clinics
  12.4.3. Diagnostic Centers
  12.4.4. Research Institutes
12.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
  12.5.1. Japan
  12.5.2. China
  12.5.3. India
  12.5.4. ASEAN
  12.5.5. Australia & New Zealand
  12.5.6. Rest of Asia-Pacific
12.6. Asia-Pacific Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User,and Country, 2017 – 2023
12.7. Europe Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends

13. LATIN AMERICA RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Diagnostic Radiopharmaceuticals
    13.1.1.1. SPECT Radiopharmaceuticals
    13.1.1.2. PET Radiopharmaceuticals
  13.1.2. Therapeutic Radiopharmaceuticals
    13.1.2.1. Beta Emitters
    13.1.2.2. Alpha emitters
    13.1.2.3. Brachytherapy
    13.1.2.4. Others
13.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.2.1. Oncology
  13.2.2. Neurological disorders
  13.2.3. Cardiovascular diseases
  13.2.4. Thyroid
  13.2.5. Others
13.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.3.1. Oral
  13.3.2. Inhalation
  13.3.3. Parenteral
13.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.4.1. Hospitals
  13.4.2. Clinics
  13.4.3. Diagnostic Centers
  13.4.4. Research Institutes
13.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  13.5.1. Brazil
  13.5.2. Mexico
  13.5.3. Argentina
  13.5.4. Venezuela
  13.5.5. Rest of Latin America
13.6. Latin America Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Country, 2017 – 2023
13.7. Latin America Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends

14. MIDDLE EAST AND AFRICA RADIOPHARMACEUTICALS (NUCLEAR MEDICINE) MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

14.1. Product Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  14.1.1. Diagnostic Radiopharmaceuticals
    14.1.1.1. SPECT Radiopharmaceuticals
    14.1.1.2. PET Radiopharmaceuticals
  14.1.2. Therapeutic Radiopharmaceuticals
    14.1.2.1. Beta Emitters
    14.1.2.2. Alpha emitters
    14.1.2.3. Brachytherapy
    14.1.2.4. Others
14.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.2.1. Oncology
  14.2.2. Neurological disorders
  14.2.3. Cardiovascular diseases
  14.2.4. Thyroid
  14.2.5. Others
14.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.3.1. Oral
  14.3.2. Inhalation
  14.3.3. Parenteral
14.4. End-User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
  14.4.1. Hospitals
  14.4.2. Clinics
  14.4.3. Diagnostic Centers
  14.4.4. Research Institutes
14.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  14.5.1. Gulf Cooperation Council (GCC) Countries
  14.5.2. Israel
  14.5.3. South Africa
  14.5.4. Rest of MEA
14.6. MEA Radiopharmaceuticals (Nuclear Medicine) Market - Opportunity Analysis Index, By Product Type, By Application, By Route of Administration, By End-User, and Country, 2017 – 2023
14.7. MEA Radiopharmaceuticals (Nuclear Medicine) Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Disease Type & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  15.2.1. Advanced Accelerator Applications S.A. (France)
  15.2.2. Bayer AG (Germany)
  15.2.3. Bracco Imaging S.p.A (Italy)
  15.2.4. Cardinal Health, Inc. (U.S.)
  15.2.5. Eli Lilly and Co. (U.S.)
  15.2.6. GE Healthcare (U.S.)
  15.2.7. IBA Molecular Imaging (Belgium)
  15.2.8. Jubilant Life Sciences Ltd (India)
  15.2.9. Lantheus Medical Imaging, Inc. (U.S.)
  15.2.10. Mallinckrodt plc (Ireland)
  15.2.11. Navidea Biopharmaceutical (U.S.)
  15.2.12. Nordion, Inc. (Canada)
  15.2.13. Siemens Healthineers (Germany)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS


More Publications